Abstract: Systemic therapy for advanced hepatocellular carcinoma (HCC) has been focusing on overcoming tumor angiogenesis and immunosuppression. Myeloid-derived suppressor cells (MDSCs) promote both angiogenesis and immunosuppression in the tumor microenvironment (TME). Multiple clinical studies have demonstrated the prognostic implications of and suggested the translational significance of MDSCs in patients with HCC. In preclinical HCC models, targeting MDSCs has been shown to enhance antitumor efficacy of sorafenib or immune checkpoint inhibitors. Reversing the protumor effects of MDSCs could be achieved by depleting MDSCs, blocking MDSC trafficking and migration into TME, and inhibiting the immunosuppressive functions of MDSCs. To date, these strategies have not yet been validated to be clinically useful in patients with malignancy including HCC. Future studies should focus on identifying specific markers for human MDSCs and developing combination approaches incorporating MDSC-targeting therapy in the treatment of HCC.
Introduction
Primary liver cancer, of which the vast majority of cases are hepatocellular carcinoma (HCC), has been the leading cause of cancer mortality worldwide for decades. The GLOBOCAN 2018 database estimated that 841,000 new cases of primary liver cancer and 782,000 deaths from it would occur annually, making it the sixth most commonly diagnosed and fourth most lethal malignancy worldwide. 1 The carcinogenesis of HCC is attributed to chronic inflammation of the liver, predominantly as a result of hepatitis B virus (HBV) and hepatitis C virus (HCV) virus infections, as well as liver cirrhosis. Owing to significant advances in the primary prevention of HBV infection through universal vaccinations as well as effective antiviral therapy for HBV and HCV infections, the incidence of HCC is expected to decline between 2035 and 2040. 2 Overall, HCC remains a significant malignant disease that will continue to be a major burden on global health for decades to come. Treatment of HCC is commonly directed by disease stage. 3 For patients with early-stage localized HCC, curative-intent treatment modalities include resection, ablation, and liver transplantation, whereas for patients with intermediate-stage localized HCC, image-guided transcatheter tumor therapies such as transarterial chemoembolization have provided survival benefits.
Unfortunately, the majority of patients with HCC either progress to or develop de novo locally advanced or metastatic diseases and are indicated for systemic therapy.
Recent advances in systemic therapy for HCC
Sorafenib, a multikinase inhibitor with antiangiogenic properties, is the first systemic therapy approved for HCC owing to two positive randomized placebo-controlled phase III trials. 4, 5 Since 2016, four other antiangiogenic agents, including three multikinase inhibitors and one antivascular endothelial growth factor receptor monoclonal antibody, have been demonstrated to provide survival benefits for patients with advanced HCC in phase III clinical trials (Table 1) . [6] [7] [8] [9] As a result, the Food and Drug
Administration of the United States (US-FDA) and the regulatory agencies of multiple countries approved lenvatinib as a first-line systemic therapy for HCC, and approved regorafenib and cabozantinib for patients with HCC who have been previously treated with sorafenib. Moreover, immunotherapy with immune checkpoint inhibitors (ICIs) such as monoclonal antibodies that target programmed cell death protein 1 (PD-1)/programmed deathligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has become a new paradigm of treatment for multiple cancers, including HCC. Nivolumab, an anti-PD-1 monoclonal antibody, induced a considerable and durable objective tumor response in patients with advanced HCC in a phase I/II study. 10 Pembrolizumab, another anti-PD-1 monoclonal antibody, exhibited a similar response rate (RR) to nivolumab in patients with HCC who had previously been treated with sorafenib in a phase II study. 11 Nivolumab and pembrolizumab were granted accelerated approval for the treatment of HCC in 2017 and 2018, respectively, by the US-FDA (Table 1) . Overall, two classes of drugs now exist to treat patients with advanced HCC: one targets tumor angiogenesis and the other targets immunosuppression. Tumor angiogenesis and immune evasion are two major "cancer hallmarks". 12, 13 Efforts have been ongoing to develop strategies that combine antiangiogenic therapy with PD-1/PD-L1 inhibitors in patients with advanced HCC. [14] [15] [16] However, new studies that elucidate the mechanisms underlying angiogenesis promotion and immunosuppression of HCC may help inspire the development of new therapeutic strategies in the future.
Myeloid-derived suppressor cells: dual tumor-supporting effects by promoting immunosuppression and angiogenesis
Myeloid-derived suppressor cells (MDSCs) play a critical role in the immune tumor microenvironment (TME depletes L-arginine and leads to cell cycle arrest in the G0-G1 phase of tumor-infiltrating T cells. Depleted L-arginine, increased NO production by iNOS, and increased ROS all result in the downregulation or desensitization of the T-cell receptor and induction of T-cell anergy. IDO degrades L-tryptophan and leads to the suppression of T and NK cells and activation of Treg. 20 Studies have also suggested that the immunosuppressive mechanisms of MDSCs may vary at different sites. In peripheral lymphoid structures, PMN-MDSCs have a high level of ROS production and suppress T cells function in an antigen-specific manner. By contrast, M-MDSCs suppress not only antigen-specific but also nonspecific T-cell responses by expressing various factors such as ARG1, NO, TGF-β, and IL-10. In TME, because of hypoxia, ROS levels in PMN-MDSCs are substantially reduced; however, the levels of ARG1 and other factors responsible for nonspecific T-cell suppression are increased. 17 Additionally, MDSCs influence TME by inducing tumor angiogenesis through the production of several angiogenic factors and vascular-modulating enzymes. 21 For example, Bv8 (bombina variegata peptide 8, a homolog of endocrine-gland-derived vascular endothelial growth factor), produced by MDSCs through granulocyte colony-stimulating factor (G-CSF)-dependent STAT3 signaling, was demonstrated to promote angiogenesis and hematopoietic cell mobilization. 22 Actually, MDSC accumulation in TME was associated with tumor refractoriness to anti-VEGF treatment; anti-G-CSF therapy or anti-Bv8 therapy could enhance the responsiveness of anti-VEGF treatment.
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Moreover, matrix metalloproteinase-9 (MMP-9)-expressing CD11b + myelomonocytic cells have been shown to be critical for the formation of tumor vasculature. Tumor growth could be inhibited in MMP-9 knockout mice or by the deletion of MMP-9 in CD11b + Gr1 + MDSCs. 25, 26 In addition, MDSCs could acquire endothelial cell properties in TME and directly incorporate into tumor endothelium. 26 
Clinical significance of MDSCs in human HCC
Previous studies have demonstrated the role of MDSCs in various chronic liver diseases such as HBV or HCV-related hepatitis, and non-alcoholic fatty liver disease (NAFLD). [27] [28] [29] [30] MDSCs were shown to inhibit T cells and moderate HBV-related liver damage during viral replication through ARG1-dependent manner. 27 MDSCs may protect liver from detrimental necroinflammation, but also contribute to persistence of HBV infection. 31 HCV infection could induce MDSCs, which suppressed T cells and antiviral NK cell responses via ROS and ARG1. 28, 29 Moreover, MDSCs accumulated in the livers of NAFLD mice and had strong suppression effect on T cells, which was dependent on NO production by iNOS. 30 Clinical studies of MDSCs in HCC have mainly focused on analyzing M-MDSCs in the peripheral blood of patients with HCC, probably because the cryopreservation process may negatively affect PMN-MDSCs. 32 Several groups have studied M-MDSCs, defined by CD14 + HLA-DR −/low cells, in the peripheral blood mononuclear cells (PBMCs) of patients with HCC. They found that these MDSCs increased in the PBMCs of patients with HCC compared with patients with only hepatitis or cirrhosis and healthy controls. [33] [34] [35] Moreover, a high frequency of MDSCs in PBMCs has been associated with aggressive tumor features and poor clinical outcomes after hepatectomy, local ablation, or hepatic arterial infusion chemotherapy. [34] [35] [36] Another report defined Table 3 summarizes the results of studies on MDSCs in patients with HCC, emphasizing the immunosuppressive activities and prognostic implications of MDSCs. Furthermore, the inhibition of CCRK enhanced the antitumor effect of anti-PD-L1 therapy. 47 Overall, preclinical studies using mouse liver cancer models not only confirmed the roles of MDSCs in tumor formation and progression but also indicated the effects of MDSCs in the treatment efficacies of sorafenib and ICIs against HCCs (Table 4) . Most studies have indicated that targeting MDSCs would improve the efficacy of sorafenib or ICIs-the currently approved therapeutic agentsin HCC.
Targeting MDSCs in the treatment of human HCC: clinical evidence to date
Numerous preclinical studies have investigated targeting MDSCs as a therapeutic strategy to improve tumor control in experimental animal models. Reversing the protumor effects of MDSCs could be achieved by depleting MDSCs, blocking MDSC trafficking and migration into TME, and inhibiting the immunosuppressive function of MDSCs (Figure 1 ). The scientific rationales and potential approaches of targeting MDSCs as cancer treatment have been previously reviewed by several groups.
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Herein, we discuss the clinical data concerning HCC by focusing on agents or approaches that have been directly or indirectly implicated in targeting MDSCs in preclinical studies.
Depletion of MDSCs
The number of MDSCs of cancer-bearing hosts could be reduced by inhibiting the myelopoiesis of bone marrow and inducing apoptosis of MDSCs; both these effects are commonly induced by chemotherapeutic agents. Indeed, several chemotherapeutic agents, including gemcitabine, doxorubicin, paclitaxel, and 5-fluorouracil (5-FU), have been investigated in preclinical studies and demonstrated to reduce the number of MDSCs in circulation and in TME. [51] [52] [53] [54] Clinical trials conducted a decade or two ago, most of which were small-scale single-arm phase II trials, demonstrated objective tumor RRs ranging from 0% to 33% for the aforementioned agents in patients with advanced HCC. [55] [56] [57] [58] [59] [60] [61] [62] However, the successful use of Abbreviations: MDSCs, myeloid-derived suppressor cells; PB, peripheral blood; LN, lymph node; HCC, hepatocellular carcinoma; TLR, Toll-like receptor; DC, dendritic cell; MHC, major histocompatibility complex; HIF-1, hypoxia-inducible factor-1; ENTPD2, ectonucleoside triphosphate diphosphohydrolase 2; CCRK, cell cycle-related kinase; PD-L1, programmed death-ligand 1.
systemic chemotherapy in the treatment of HCC has been hampered by the inevitable toxicities associated with maximum tolerated dose-type chemotherapy and the poor toleration by patients with HCC because of impaired organ function and decreased bone marrow reserves. Administration of chemotherapeutic agents in a lowdose and uninterrupted manner is referred to as metronomic chemotherapy. Metronomic chemotherapy was originally described as an antiangiogenic chemotherapy 63 and has recently been demonstrated to modulate TME, including through an effect on the immune system. 64, 65 Notably, Servo et al demonstrated in a mouse melanoma model that an ultralow and nontoxic dose of paclitaxel could reduce MDSC numbers, improve immunosuppressive functions, and prolong the survival of tumor-bearing mice. 53 Clinical studies of metronomic chemotherapy have been conducted in patients with advanced HCC, mainly using oral 5-FU preparations either alone or in combination of GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; VEGF, vascular endothelial growth factor; G-CSF, granulocyte colony-stimulating factor; SCF, stem cell factor; IFN-γ, interferon-γ; PGE2, prostaglandin E2; ARG1, arginase; IDO, indoleamine 2,3-dioxygenase; NO, nitric oxide; DC, dendritic cell, T, T cell; Treg, regulatory T cell; Mϕ, macrophage; ENTPD2, ectonucleoside triphosphate diphosphohydrolase 2; CCLs, CC chemokine ligands; CXCLs, C-X-C chemokine ligands; TME, tumor microenvironment; iNOS, inducible nitric oxide synthase.
antiangiogenic agents. [66] [67] [68] [69] A recent preclinical study demonstrated that MDSCs could be selectively targeted by TRAIL receptor 2 (TRAIL-R2/DR5) agonist. 76 A phase I trial testing the agonistic TRAIL-R2 antibody DS-8273a in patients with advanced cancer, including HCC, found that DS-8273a eliminated MDSCs without affecting mature myeloid or lymphoid cells, and the decrease in MDSCs was associated with progression-free survival (PFS). 77 Another randomized phase II study evaluated tigatuzumab, a humanized monoclonal antibody directed against TRAIL-R2, in patients with advanced HCC. 78 Although patients treated with tigatuzumab plus sorafenib had numerically longer median PFS and overall survival than those treated with sorafenib alone, the differences did not reach statistical significance. The combination of tigatuzumab with sorafenib was well tolerated in patients with HCC; however, the effect on MDSCs was not investigated. Another strategy to reduce the number of MDSCs in TME is to facilitate MDSCs differentiating into dendritic cells and macrophages. This MDSC differentiation strategy can be achieved through the inhibition of retinoic acid signaling using all-trans retinoid acid (ATRA). 79 ATRA has been determined in clinical trials to downregulate MDSCs, and a significant reduction of MDSCs was observed in patients with renal cell carcinoma and smallcell lung cancer. 80, 81 A case report by Hungarian investigators detailed how a patient received ATRA treatment for hematological malignancy and experienced significant tumor remission in liver tumors, which were clinically diagnosed as HCC because of moderately elevated alfa-fetoprotein and the presence of portal vein thrombosis. 82 In addition, polyprenoid acid, a synthetic retinoid derivative, has been demonstrated to prevent second primary HCCs in patients who underwent surgical resection for HCC. 83, 84 Polyprenoid acid may work through multiple mechanisms to achieve its chemopreventive effect on HCC. 85, 86 However, whether it would affect anticancer immunity or MDSCs is unclear.
Blockade of MDSC trafficking
Entry of MDSCs into TME is critical for their main immunosuppressive function to be manifested. Therefore, inhibiting chemokine receptors may reduce the number of MDSCs in TME. Chemokine receptor CCR2 and the interaction of its ligand CCL2 are required not only for the recruitment of M-MDSCs and tumor-associated macrophages but also for their suppressive function. 87, 88 A CCR2 inhibitor, PF-04136309, has been tested in combination with FOLFIRINOX chemotherapy in a phase Ib clinical trial of patients with advanced pancreatic cancer. Compared with patients who received FOLFIRINOX alone, those who received chemotherapy plus PF-04136309 had a significantly lower ratio of blood to bone marrow CCR2-positive monocytes, demonstrating the effect of CCR2 blockade on the inhibition of the mobilization of bone marrowderived monocytes into circulation.
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CCR5 is another chemokine receptor that is expressed in many immune cells, and the CCR5-CCR5 ligand axis was found to be critical for the mobilization of PMNMDSCs. 90 Targeting CCR5 + MDSCs has been demonstrated to prevent MDSC migration and suppress tumor growth in preclinical studies. 91, 92 Recently, a phase Ib/2 clinical trial testing a small-molecule CCR2/5 dual antagonist, BMS-813160, as monotherapy or in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer began to recruit patients.
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CXCR2 is another chemokine receptor expressed on PMN-MDSCs and tumor-associated neutrophils. Blocking CXCR2 has limited the recruitment of PMN-MDSCs and enhanced the efficacy of anti-PD-1 therapy or chemotherapy in preclinical studies. 94, 95 However, there has been no clinical development of inhibitors of these chemokine receptors in HCC.
Inhibition of the immunosuppressive function of MDSCs
STAT3 is a critical transcription factor for immunosuppressive activity and proliferation of MDSCs. A STAT3 oligonucleotide inhibitor, danvatirsen (AZD9150), was tested in a phase I clinical trial of patients with advanced HCC (NCT01839604); 39 patients with HCC actually received the study agent in the escalation or expansion cohort, and only one patient in the escalation cohort had a partial response. The most common adverse events were transaminase elevation and thrombocytopenia. 96 In a recent phase Ib/2 study testing danvatirsen with or without durvalumab, an anti-PD-L1 antibody, in patients with head and neck squamous cell carcinoma (HNSCC), no responses were reported to monotherapy with danvatirsen; however, a relatively high RR of 23% was reported in the danvatirsen plus durvalumab combination arm. 97 Histone deacetylase (HDAC) inhibitors may suppress MDSC function by reducing ARG1, iNOS, and COX-2 levels. 98 Entinostat, a class I HDAC inhibitor, was demonstrated to inhibit the immunosuppressive function of both PMN-MDSCs and M-MDSCs in lung cancer and renal cancer mouse models. The antitumor effect of PD-1 blockade was also enhanced by adding entinostat in vivo. 98 Several clinical trials have tested various HDAC inhibitors in HCC. 99, 100 Although these agents were generally tolerated, their activities as single-agent appeared to be low because of low RRs and short PFS. Further, the effect of such therapy on MDSCs was not evaluated. Phosphodiesterase-5 (PDE-5) inhibition downregulated ARG1 and iNOS activities in several preclinical models. [101] [102] [103] Tadalafil, the FDA-approved PDE-5 inhibitor, has been tested in HCC mouse models; MDSC suppressor function was reversed and the antitumor effect of cytokine-induced killer-cell therapy was enhanced by the addition of tadalafil. 103 Tadalafil has been tested in clinical trials of patients with HNSCC and melanoma, but not in patient with HCC. The treatment was well tolerated, MDSCs were suppressed in circulation and tumor tissues, and T cell immunity was determined to be elevated. [104] [105] [106] Targeting MDSCs in the treatment of HCC: future perspectives
Ensuring that the targeting MDSCs is a clinically useful therapy is challenging because of the following reasons. First, MDSCs are a heterogeneous group of immature myeloid cells that require multiple markers to define and differentiate their subtypes. In humans, no single-specific marker exists for defining MDSCs or their subtypes. This limitation makes direct demonstration of MDSCs in human HCC tumors and tracking their dynamic changes in humans cumbersome. Lack of specific makers also renders the development of "targeted therapy" for specifically targeting MDSCs difficult in humans. Second, although multiple therapeutic strategies focusing on depleting, inhibiting the trafficking, and downregulating the immunosuppressive function of MDSCs have been proposed in preclinical models, most agents have exhibited multiple biological functions, thereby making the true contribution of targeting MDSCs to therapeutic effects less convincing. Third, the clinical data of potential MDSCstargeting agents, revealed by preclinical studies, suggest that these strategies when administered alone are of limited efficacy against HCC. Therefore, future studies should focus on identifying specific markers of and developing reliable assays for detecting human MDSCs and their subtypes. Specific markers will be invaluable for helping to develop more specific approaches for targeting MDSCs. Assays that could reliably detect MDSCs in both circulation and tissues, and in freshly prepared and archival samples, are of great importance for confirming the significance of MDSCs in patients with HCC who undergo therapeutic approaches. Furthermore, future studies should focus on developing combined approaches for treating HCC, especially those that incorporate MDSC-targeting therapy with ICIs or antiangiogenic agents, the two approved therapeutic strategies for treating HCC.
In conclusion, MDSCs play critical roles in promoting immunosuppression and angiogenesis, two major "cancer hallmarks" and two crucial therapeutic targets for HCC. The prognostic significance of MDSCs has been demonstrated in multiple clinical studies of patients with HCC. Thus, targeting MDSCs may be a potential therapeutic strategy for treating HCC. Although multiple preclinical studies have demonstrated the promising therapeutic efficacy of targeting MDSCs, additional well-designed clinical studies incorporating strong immunological, molecular, and biochemical research are warranted for the successful development of targeting MDSCs in the treatment of HCC.
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